First report of trastuzumab treatment after postoperative Takotsubo cardiomyopathy.

Mickaël Burgy, Hélène Brossat, Philippe Barthélémy, Alessio Imperiale, Annie Trinh, Chafia Assia Hazam, Jean‐Pierre Bergerat, Carole Mathelin

PubMed · 2014 · 13 citations · 7 references

Concepts

Abstract

BACKGROUND: Trastuzumab is a humanized monoclonal antibody used for the treatment of HER2-positive breast cancer. Cardiotoxicity is a well-known adverse event of trastuzumab use but little has been documented regarding its use in patients with a history of cardiac disease. CASE REPORT: We describe a case in which trastuzumab treatment was administered to a 40-year-old female patient with early breast cancer after acute heart failure secondary to postoperative Takotsubo cardiomyopathy. After one year of follow-up with close monitoring by echocardiography, there have been no heart-related symptoms. Additional surgery was performed because of positive resection margins at first surgery, without complications, despite the risk of recurrence of Takotsubo cardiomyopathy. CONCLUSION: Trastuzumab can be safely administered after acute heart failure secondary to postoperative Takotsubo cardiomyopathy.

References

7